Search

Displaying results 1861 - 1870 of 10000 in total
  1. Drug

    Bromocriptine

    go.drugbank.com/drugs/DB01200
    ApprovedInvestigationalWithdrawn

    Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. … In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use.

    Categories: Heterocyclic Compounds with 4 or More RingsProducts: AA PHARMA BROMOCRIPTINE TABLET 2.5 mg
  2. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. … Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.

    Categories: Heterocyclic Compounds with 4 or More Rings
  3. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition

  4. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    Penpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  5. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine.

  6. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. … [A237054] Anifrolumab has also been investigated for the treatment of Scleroderma.[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929]

    Products: SAPHNELO 300MG CONCENTRATE FOR SOLUTION FOR INFUSION
  7. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. … Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

  8. Target

    Potassium channel subfamily K member 2

    go.drugbank.com/bio_entities/BE0000210
    TargetHumans

    K(+) channel that conducts voltage-dependent outward rectifying currents upon membrane depolarization. Voltage sensing is coupled to K(+) electrochemical gradient in an 'ion flux gating' mode where outward but not inward ion flow opens t...

    Synonyms: Two pore potassium channel TPKC1, Two pore domain potassium channel TREK1
  9. Drug

    Coagulation factor VIIa Recombinant Human

    go.drugbank.com/drugs/DB00036
    ApprovedInvestigational

    Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. … NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.

    Products: powder and solvent for solution for injection 2mg, NOVOSEVEN 2MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
  10. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262076] Patients with cTTP have a severe deficiency of a plasma metalloproteinase called ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible … [A262076] It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP.